Anders Lilja

This inventor holds 5 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignees: Glaxosmithkline Biologicals Sa, Hookipa Biotech Gmbh. Active years: 2019-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Anders Lilja. Retrieved from https://idiyas.com/inventor/anders-lilja

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5 (Patent Applications = 1)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 6.0

ph-index = 2

Forward Citations = 44(Granted Patents)

Location History:

Vienna, AT (2019 - 2022)
Somerville, MA (US) (2021 - 2023)

Company Filing History:

3 out of 545

Glaxosmithkline Biologicals Sa

Years Active: 2019-2023

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11639370 - Antigen delivery platforms (2023-05-02),

2. 11407790 - HPV vaccines (2022-08-09),

3. 11078237 - Antigen delivery platforms (2021-08-03),

4. 10669315 - HPV vaccines (2020-06-02),

5. 10414802 - Mammalian cells expressing cytomegalovirus antigens (2019-09-17),

Title: The Innovative Contributions of Anders Lilja

Introduction

Anders Lilja is a prominent inventor based in Vienna, Austria, known for his significant contributions to the field of biotechnology. With a total of five patents to his name, he has made remarkable advancements in vaccine development and therapeutic methods.

Latest Patents

Among his latest patents, Anders has developed antigen delivery platforms that focus on delivering herpes virus proteins to cells. These platforms are designed to elicit potent neutralizing antibodies, thereby generating broad immune responses that are beneficial for vaccine development. Additionally, he has worked on genetically modified arenaviruses that serve as vaccines against neoplastic diseases, including various cancers associated with Human Papillomavirus (HPV). His inventions also encompass pharmaceutical compositions and methods aimed at preventing or treating infections that lead to neoplastic diseases.

Career Highlights

Throughout his career, Anders has collaborated with notable companies such as GlaxoSmithKline Biologicals and Hookipa Biotech GmbH. His work has been instrumental in advancing the understanding and treatment of viral infections and cancer.

Collaborations

Anders has worked alongside talented individuals like Michael Franti and Rebecca Loomis, contributing to a collaborative environment that fosters innovation and research.

Conclusion

Anders Lilja's innovative work in vaccine development and therapeutic methods highlights his importance in the field of biotechnology. His contributions continue to pave the way for advancements in medical science and public health.

Profile summary based on public USPTO records.